Page last updated: 2024-11-09

benzylthiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID737375
CHEMBL ID1087841
SCHEMBL ID133802
MeSH IDM0114346

Synonyms (40)

Synonym
AC-17452
STL301850
thiourea, (phenylmethyl)-
nsc15510
nsc-15510
urea, 1-benzyl-2-thio-
benzylthiourea
621-83-0
amino[benzylamino]methane-1-thione
1-benzylthiourea
HMS1724A04
CHEMBL1087841 ,
AKOS000120851
A833632
nsc 15510
mrp6y7412k ,
unii-mrp6y7412k
einecs 210-709-9
n-benzylthiourea
1-benzyl-2-thiourea
bdbm50356170
FT-0622865
SCHEMBL133802
9be ,
benzyl-2-thiourea
n-benzyl thiourea
benzylthioharnstoff
STR05661
n-benzylthiourea #
thiourea, n-(phenylmethyl)-
B4612
DTXSID40211158
mfcd00041370
F0001-1655
EN300-17270
Q27284198
D85863
carpasemine
SY049909
Z56900892
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)25.40000.03403.987110.0000AID626570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID480030Inhibition of melanogenesis in mouse B16 cells2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells.
AID626569Inhibition of mushroom tyrosinase activity using L-tyrosine as substrate at 10 uM by spectrometric analysis2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Structural requirement of phenylthiourea analogs for their inhibitory activity of melanogenesis and tyrosinase.
AID480029Inhibition of melanogenesis in mouse B16 cells at 10 uM2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells.
AID626570Inhibition of mushroom tyrosinase activity using L-tyrosine as substrate by spectrometric analysis2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Structural requirement of phenylthiourea analogs for their inhibitory activity of melanogenesis and tyrosinase.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's1 (7.69)18.2507
2000's6 (46.15)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]